Article: Aetna Agrees with SNMMI, Updates Coverage Policy

Since earlier this year, the Society of Nuclear Medicine and Molecular Imaging has worked to change Aetna's stance on the use of Dotatate and Fluciclovine, two radiopharmaceutical's used in the early detection of cancer. At the time Aetna has claimed that both are "experimental and investigational," while SNMMI made the case that recent advances have proven otherwise.

Just this month Aetna expanded their coverage, now including gallium-68 (Ga-68) dotatate PET, upgrading its prior "experimental" status to now “medically necessary.”

Thanks to these efforts of SNMMI and its more than 15,000 members, greater access to these treatment options may help lead to better patient outcomes.

Read more about this news here.

Seth Werkheiser